Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once ...
The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...
(VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of ...
Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...
According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...
Discover Vertex Pharmaceuticals' groundbreaking patent for variant PD-1 polypeptides, enhancing immunomodulatory proteins for innovative cancer and immune therapies.
The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback